Belpointe Asset Management’s Galectin Therapeutics GALT Stock Holding History

Belpointe Asset Management’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$65.6K	Sell	14,139 -92,000	-87%	-$238K	﹤0.01%	1109
2026 Q1	$296K	Hold	106,139	–	–	0.01%	875
2025 Q4	$442K	Buy	+106,139	New	+$559K	0.02%	697
2023 Q2	–	Sell	-1,066	Closed	-$2.24K	–	1613
2023 Q1	$2.24K	Hold	1,066	–	–	﹤0.01%	3280
2022 Q4	$1.21K	Buy	+1,066	New	+$1.42K	﹤0.01%	3400
2019 Q3	–	Sell	-29,228	Closed	-$121K	–	687
2019 Q2	$121K	Buy	29,228 +2,230	+8%	+$9.66K	0.02%	539
2019 Q1	$138K	Buy	+26,998	New	+$130K	0.03%	376
2018 Q4	–	Sell	-31,129	Closed	-$187K	–	547
2018 Q3	$187K	Sell	31,129 -12,427	-29%	-$68.4K	0.03%	468
2018 Q2	$277K	Buy	+43,556	New	+$212K	0.08%	276

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Belpointe Asset Management's GALT Position: Q2 2026 in Review

Belpointe Asset Management reduced its Galectin Therapeutics (GALT) stake by 87% in Q2 2026, selling an estimated $238K and leaving 14,139 shares worth $65.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1109.

Belpointe Asset Management first reported a position in GALT in Q2 2018 and has held it in 9 quarters since. The position peaked at $442K in Q4 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

Belpointe Asset Management held 14,139 shares of Galectin Therapeutics worth $65.6K as of Q2 2026.
Belpointe Asset Management sold 92,000 Galectin Therapeutics shares in Q2 2026, an estimated $238K.
Galectin Therapeutics made up ﹤0.01% of Belpointe Asset Management's portfolio in Q2 2026, its #1109 holding.
Belpointe Asset Management first reported a position in Galectin Therapeutics in Q2 2018 and has held it in 9 quarters since.
Belpointe Asset Management's Galectin Therapeutics position peaked at $442K in Q4 2025.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Belpointe Asset Management's 13F filing for Q2 2026, filed 31 Jul 2026.